S T Ong

List of Publications by Year
in descending order

47 papers	2,076 citations	430874 18 h-index	289244 40 g-index
47 all docs	47 docs citations	47 times ranked	3117 citing authors

#	Article	IF	Citations
1	Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica, 2022, 107, 358-370.	3.5	10
2	THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. International Journal of Molecular Sciences, 2022, 23, 1207.	4.1	4
3	Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia. Leukemia, 2022, 36, 892-896.	7.2	2
4	RCA2: a scalable supervised clustering algorithm that reduces batch effects in scRNA-seq data. Nucleic Acids Research, 2021, 49, 8505-8519.	14.5	7
5	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020, 135, 2337-2353.	1.4	49
6	SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. Leukemia, 2020, 34, 1787-1798.	7.2	12
7	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation doubleâ€positive lung cancer. Cancer Science, 2020, 111, 561-570.	3.9	31
8	Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with <i>BIM</i> deletion polymorphism. Journal of Medical Investigation, 2020, 67, 343-350.	0.5	3
9	PML-RAR Binds to the +7kb Enhancer of CEBPE and Inhibits Its Expression. Blood, 2020, 136, 43-43.	1.4	0
10	BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. Leukemia and Lymphoma, 2019, 60, 234-237.	1.3	5
11	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 2019, 33, 1835-1850.	7.2	97
12	Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches. Scientific Reports, 2018, 8, 15028.	3.3	12
13	The arginase inhibitor NÏ‰â˜hydroxyâ˜norâ˜arginine (norâ˜NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS ONE, 2018, 13, e0205254.	2.5	8
14	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphismâ€“Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2017, 23, 3139-3149.	7.0	69
15	Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides. Oncotarget, 2017, 8, 77567-77585.	1.8	18
16	The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia. PLoS ONE, 2017, 12, e0174107.	2.5	17
17	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget, 2017, 8, 41474-41486.	1.8	13
18	Structureâ€“Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. Journal of Medicinal Chemistry, 2016, 59, 3063-3078.	6.4	16

#	Article	IF	Citations
19	The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. Oncotarget, 2016, 7, 2721-2733.	1.8	16
20	Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance. , 2016, , 167-182.		1
21	The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. Blood, 2015, 126, 3737-3737.	1.4	3
22	Identification of cis-Acting Elements and Splicing Factors Involved in the Regulation of BIM Pre-mRNA Splicing. PLoS ONE, 2014, 9, e95210.	2.5	21
23	Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood, 2014, 123, 3316-3326.	1.4	87
24	Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. Nature Medicine, 2014, 20, 1090-1091.	30.7	8
25	A novel Bcr-Ablâ€“mTORâ€“eIF4A axis regulates IRES-mediated translation of LEF-1. Open Biology, 2014, 4, 140180.	3.6	21
26	Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia. PLoS ONE, 2014, 9, e103435.	2.5	9
27	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget, 2014, 5, 9033-9038.	1.8	56
28	Targeting of the MNKâ€“eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2298-307.	7.1	132
29	Dual Specific Inhibitors Of The BCR-ABL and MNK Kinases As Potential Therapeutics For Blast Crisis Chronic Myeloid Leukemia. Blood, 2013, 122, 2702-2702.	1.4	1
30	The BIM Deletion Polymorphism: A Paradigm Of a Permissive Interaction Between Germline and Acquired TKI Resistance Factors In Chronic Myeloid Leukemia. Blood, 2013, 122, 3977-3977.	1.4	0
31	The BCL-2 Inhibitor ABT-199 Enhances Imatinib-Induced Cell Death In Chronic Phase CML Progenitors. Blood, 2013, 122, 3978-3978.	1.4	1
32	Multi-Agent Chemotherapy Overcomes Steroid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 2544-2544.	1.4	0
33	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 2012, 18, 521-528.	30.7	510
34	The Role of Protein Phosphorylation in Therapy Resistance and Disease Progression in Chronic Myelogenous Leukemia. Progress in Molecular Biology and Translational Science, 2012, 106, 107-142.	1.7	8
35	Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function. Blood, 2011, 118, 963-963.	1.4	1
36	Physiologic Hypoxia Promotes Maintenance of CML Stem Cells Despite Effective BCR-ABL Inhibition. Blood, 2011, 118, 450-450.	1.4	0

#	Article	IF	Citations
37	A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia. Blood, 2011, 118, 1666-1666.	1.4	0
38	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine, 2010, 16, 205-213.	30.7	329
39	Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance. Molecular and Cellular Biology, 2008, 28, 6496-6509.	2.3	55
40	A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene, 2007, 26, 1188-1200.	5.9	46
41	Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia. European Journal of Haematology, 2006, 76, 444-446.	2.2	12
42	Expression profiling of a transformed thymocyte cell line undergoing maturation in vitro identifies multiple genes involved in positive selection. Cellular Immunology, 2003, 221, 64-79.	3.0	9
43	Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia. Oncogene, 1999, 18, 79-85.	5.9	20
44	Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene, 1998, 16, 2333-2343.	5.9	70
45	Precise localization of theFHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affectFHIT transcription in tumor cell lines. , 1997, 20, 16-23.		24
46	Direct Cloning of DNA Sequences from the Common Fragile Site Region at Chromosome Band 3p14.2. Genomics, 1996, 35, 109-117.	2.9	52
47	Chemotherapy in malignant pleural mesothelioma. A review.. Journal of Clinical Oncology, 1996, 14, 1007-1017.	1.6	211